Friedrich Miescher Institute for Biomedical Research

ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

Retrieved on:

Thursday, October 5, 2023

CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer. Dr. Pullen brings over 20 years of leadership experience in the biopharmaceutical space and has led drug discovery programs spanning multiple gene classes, modalities and indications, including oncology, neuroscience and immunology. In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.

Key Points:

and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer.
In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.
"We are pleased to welcome Nick to our team at this pivotal time for ARTBIO.
Nick brings a wealth of highly relevant and valuable expertise in discovery and development of innovative therapies across multiple disease areas," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.

ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer

Retrieved on:

Thursday, October 5, 2023

CAMBRIDGE, Mass. and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer. Dr. Pullen brings over 20 years of leadership experience in the biopharmaceutical space and has led drug discovery programs spanning multiple gene classes, modalities and indications, including oncology, neuroscience and immunology. In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.

Key Points:

and OSLO, Norway and LONDON and BASEL, Switzerland, Oct. 5, 2023 /PRNewswire/ -- ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), today announced the appointment of Nick Pullen, Ph.D., as Chief Scientific Officer.
In this role, Dr. Pullen will be responsible for overseeing all scientific research efforts to further leverage ARTBIO's scientific approach to radiopharmaceuticals and progress the company's differentiated pipeline.
"We are pleased to welcome Nick to our team at this pivotal time for ARTBIO.
Nick brings a wealth of highly relevant and valuable expertise in discovery and development of innovative therapies across multiple disease areas," said Emanuele Ostuni, Ph.D., Chief Executive Officer of ARTBIO.

MRES: M2Bio Sciences Appoints Adrian J. Maizey, Accomplished CEO and Financial Expert, to Advisory Board

Retrieved on:

Wednesday, July 19, 2023

Prior to his role at Rand Capital, Adrian held several key positions in prestigious financial and investment firms, showcasing his versatile capabilities.

Key Points:

Prior to his role at Rand Capital, Adrian held several key positions in prestigious financial and investment firms, showcasing his versatile capabilities.
Expressing his excitement about joining M2Bio Sciences' Advisory Board, Adrian Maizey said, "Joining M2Bio Sciences is invigorating.
Jeff Robinson, CEO of M2Bio Sciences, warmly welcomed Adrian Maizey to the Advisory Board, stating, "We are thrilled to have Adrian Maizey on board with us.
Adrian Maizey's appointment to the Advisory Board further reinforces M2Bio Sciences' commitment to fostering innovation and advancing transformative solutions in the biotechnology arena.

MRES: M2Bio Sciences Unveils Explainer Video Showcasing Groundbreaking NFTs and Altcoins for Drug Discovery, Revolutionizing Investment Access

Retrieved on:

Thursday, July 6, 2023

Drug discovery, Research, Biomedical Research, Friedrich Miescher Institute for Biomedical Research, Non-fungible token, Biomedicine, OTC, Artificial intelligence, Science, Growth, Ecosystem, Mental health, Social media, Cryptocurrency, Pharmaceutical industry

Through the implementation of non-fungible tokens (NFTs) and alternative coins (Altcoins), M2Bio Sciences aims to transform the way individuals participate in and benefit from drug discovery investments.

Key Points:

Through the implementation of non-fungible tokens (NFTs) and alternative coins (Altcoins), M2Bio Sciences aims to transform the way individuals participate in and benefit from drug discovery investments.
It emphasizes the transparency, security, and liquidity brought forth by blockchain technology, which ensures seamless and trustworthy transactions within the drug dM2Bio Sciences Unveils Explainer Video Showcasing Groundbreaking NFT and Altcoins for Drug Discovery investment landscape.
By demystifying the complex concepts behind NFTs, Altcoins, and their application in drug discovery, the video ensures that viewers gain a comprehensive understanding of this groundbreaking investment opportunity.
To view the explainer video and learn more about M2Bio Sciences' revolutionary NFTs and Altcoins for Drug Discovery, please visit the M2Bio Sciences YouTube channel found here.

MRES: Institute of Biomedical Research Announces Application for Name Change and New Ticker Symbol in Anticipation of Future M&A Activities and Senior Listing

Retrieved on:

Wednesday, July 5, 2023

Optimism, Biotechnology, Research, Biomedical Research, Friedrich Miescher Institute for Biomedical Research, Biomedicine, OTC, Artificial intelligence, Growth, Mental health, Social media, Management

CAPE TOWN, South Africa, July 5, 2023 /PRNewswire/ -- Institute of Biomedical Research Corp. (OTC PINK: MRES) ("Institute of Biomedical Research" or the "Company"), a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions, is pleased to share the following update and corporate initiatives:

Key Points:

MRES intends to undergo a name change that better reflects the company's evolving business objectives and strategic direction.
Furthermore, MRES will adopt a new ticker symbol to coincide with its name change.
Jeff Robinson, CEO of Institute of Biomedical Research, expressed optimism about the future and the opportunities that lie ahead.
MRES will keep its shareholders and the investment community informed of the progress related to the name change and new ticker symbol.

MRES: M2Bio Sciences Enters into Letter of Intent to Acquire Crypto Exchange JDAX

Retrieved on:

Tuesday, June 27, 2023

Functioning as a cutting-edge digital marketplace, JDAX empowers users to buy, sell, and hold a wide range of cryptocurrencies.

Key Points:

Functioning as a cutting-edge digital marketplace, JDAX empowers users to buy, sell, and hold a wide range of cryptocurrencies.
JDAX, the Johannesburg Digital Assets Exchange, represents a notable South African Fintech company immersed in the realms of Blockchain, Web3, and Decentralized Finance (DeFi) technologies.
Leveraging novel extraction methods and AI models, M2Bio exponentially enhances the pace of discovery and characterization of potentially bioactive compounds.
Jeff Robinson, M2Bio Sciences, Inc CEO added: "At M2Bio we are always working on finding unique ways to deploy cutting-edge technologies in order to advance medicine.

MRES: M2Bio Sciences Establishes Research Chair at The University of Pretoria for Phytomedicines

Retrieved on:

Friday, June 16, 2023

The UP Biodiscovery Centre, led by Prof Vinesh Maharaj, NAS Deputy Dean for Research and Postgraduate Education and a renowned bio-prospector, will conduct commercial natural product research and development.

Key Points:

The UP Biodiscovery Centre, led by Prof Vinesh Maharaj, NAS Deputy Dean for Research and Postgraduate Education and a renowned bio-prospector, will conduct commercial natural product research and development.
The M2Bio Sciences Research Chair will conduct research focused on science and evidence-backed premium health and wellness products over the next four years.
Although I am not a scientist, I have an enormous passion for science, technology, and medicine and how they intersect," Mr. Jeff Robinson, CEO of M2Bio Sciences stated.
The three partners, UP/NAS, M2Bio Sciences, and Enterprises UP, responded well to this great opportunity.

MRES: M2Enviro Expands R&D Efforts to Explore Diverse Classes of Mycelium Composite Materials for Commercialization

Retrieved on:

Wednesday, June 14, 2023

Furthermore, M2Enviro is looking to open more R&D pipelines to explore different classes of mycelium composite materials and their applications.

Key Points:

Furthermore, M2Enviro is looking to open more R&D pipelines to explore different classes of mycelium composite materials and their applications.
M2Enviro acknowledges this urgent challenge and is committed to greatly expanding its research and development initiatives to explore novel types of mycelium composite materials for the development of sustainable packaging solutions.
The resulting material generally exhibits significantly higher mechanical strength and durability than non-heat-pressed mycelium composite materials that are just dehydrated.
M2Enviro's commitment to sustainability and its innovative approach to mycelium composite materials are poised to reshape the packaging and material landscape.

MRES: Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions

Retrieved on:

Wednesday, June 7, 2023

Through the application of cutting-edge AI algorithms and machine learning, the company has created highly efficient nutritional assistance solutions.

Key Points:

Through the application of cutting-edge AI algorithms and machine learning, the company has created highly efficient nutritional assistance solutions.
The company has also been actively researching psychedelic compounds for potential therapeutic use in mental health disorders.
Looking forward, the Institute of Biomedical Research and M2Bio Sciences remain unwavering in their dedication to advancing biotechnology and medical solutions through AI.
Through ongoing research, innovation, and strategic partnerships, they will continue to lead the industry and improve the lives of millions.

Ajax Therapeutics Appoints Eric S. Fischer, PhD, to Scientific Advisory Board

Retrieved on:

Wednesday, May 24, 2023

Ajax Therapeutics, Inc. , a biopharmaceutical company applying computational chemistry and structure-based technologies to develop first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB).

Key Points:

Ajax Therapeutics, Inc. , a biopharmaceutical company applying computational chemistry and structure-based technologies to develop first-in-class and best-in-class JAK inhibitors for myeloproliferative neoplasms (MPNs), today announced the appointment of Eric S. Fischer, PhD, to the Company’s Scientific Advisory Board (SAB).
Dr. Fischer is a global leader in targeted protein degradation with appointments at Dana-Farber Cancer Institute (Dana-Farber) and Harvard Medical School.
He is a co-founder of Civetta Therapeutics, Neomorph, Inc. and Proximity Therapeutics.
Dr. Fischer completed his undergraduate training at the Universities of Hamburg and Basel and his doctoral training at the Friedrich Miescher Institute for Biomedical Research.